Piper Sandler Downgrades ABIOMED (ABMD) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Johnson & Johnson's (JNJ) $16.6bn Deal for Abiomed (ABMD) Deal a Positive - Stifel
November 1, 2022 10:00 AM EDTJohnson & Johnson (NYSE: JNJ) announced Tuesday that it has agreed a $16.6 billion deal to acquire heart pump maker Abiomed (NASDAQ: ABMD).
The company will pay $380 per share in cash for Abiomed, representing an over 50% premium to Abiomed's last closing price. The deal is set to be completed before the end of the first quarter of 2023. In addition, Abiomed shareholders will also receive up to $35 per share in cash if certain commercial and clinical milestones are achieved.
Johnson &... More
